chevron_leftBack
As of 16 June 2026, Annovis Bio, Inc. has a market cap of $63.54M USD, ranking #28818 globally and #4294 in the United States.
It ranks #2618 in the Healthcare sector, and #929 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$63.54MUSD
Enterprise Value
$42.95MUSD
Net Income (TTM)
-$28.85MUSD
PB Ratio
3.0
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Maria Maccecchini
open_in_new
Employees
7
Founded
2008
IPO
29 Jan 2020
Website
annovisbio.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -0.5% | -1.6% | -9.9% | -40% | -13% | 18% |
News
Loading...
ANVS Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ANVS
Annovis Bio Inc Ordinary Shares
ISIN: US03615A1088
Shares Out.:
Shares Outstanding:
34.647M1
Shares Float:
29.914M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
1.84 USD | |
|
07X
Annovis Bio Inc Ordinary Shares
ISIN: US03615A1088
|
1.62 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Annovis Bio, Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
1M%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
861K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
567K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
431K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
235K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
185K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$320.51B
504K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.14B
453K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$273.78B
431K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.97B
286K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.21B
173K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.2B
170K%
80.96B GBP
|
14.6
|
chevron_leftBack